VTV Therapeutics spikes afterhours in anticipation of AAIC data

VTv Therapeutics (NASDAQ:VTVT) has risen 8.8% postmarket after it says it will present at this week's Alzheimer's Association International Conference.
The oral presentation will cover data from its phase 3 STEADFAST study and the preceding phase 2B study of azeliragon to "further support the biological hypothesis for the potential beneficial effects of azeliragon on the ADAS-cog and CDR-sb in patients with mild Alzheimer’s disease and type 2 diabetes."
Azeliragon is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts (RAGE).

AVERAGE ANALYSTS PRICE TARGET $6.50
AVERAGE RECOMMENDATION BUY

COMPANY PROFILE
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.